 This is an investigational study. Nivolumab is FDA approved and commercially available for use in melanoma patients. Its use in this study is investigational. Ibrutinib is FDA approved and commercially available for the treatment of patients with CLLSLL. The use of these drugs in combination is considered investigational. The study doctor can explain how the drugs are designed to work. 